Skip to main content
Figure 2 | Head & Neck Oncology

Figure 2

From: The use of specific anti-growth factor antibodies to abrogate the oncological consequences of transfusion in head & neck squamous cell carcinoma: an in vitro study

Figure 2

Showing the effect of the addition of blood product supernatant upon the growth of an endothelial cell line (HUVEC). A (top left) represents a control group; B (top right) represents the control group with the addition of anti-endothelial growth factor antibody; C (bottom left) represents the effect of incubation with blood product supernatant; D (bottom left) represents the effect on HUVEC growth in media supplemented with blood product supernatant pre-incubated with anti endothelial growth factor. This is representative of the direct effects of blood product supernatant upon the cell lines studied. The effect of anti-endothelial growth factor antibodies is similar, i.e. in reducing vascular channel formation. There was a significant statistical difference between groups represented by ‘A, C and D’, but not between groups ‘A and B’ suggesting there is a direct effect of supplementation with blood product supernatant which is abrogated by the use of anti-endothelial growth factor antibody but no cytotoxic effect of the antibody per-se on the cell lines.

Back to article page

Head & Neck Oncology

ISSN: 1758-3284